Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition.

Détails

Ressource 1Télécharger: 31528826_BIB_925652F1A63C.pdf (974.99 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_925652F1A63C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition.
Périodique
Journal of the Endocrine Society
Auteur(s)
Wilson J.R., Kerman S.J., Hubers S.A., Yu C., Nian H., Grouzmann E., Eugster P.J., Mayfield D.S., Brown N.J.
ISSN
2472-1972 (Electronic)
ISSN-L
2472-1972
Statut éditorial
Publié
Date de publication
01/10/2019
Peer-reviewed
Oui
Volume
3
Numéro
10
Pages
1784-1798
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Dipeptidyl peptidase 4 (DPP4) inhibitors may increase the risk of heart failure. Decreased degradation of vasoactive peptides like substance P [also degraded by angiotensin-converting enzyme (ACE)] and Y1 agonists peptide YY (PYY 1-36) and neuropeptide Y (NPY 1-36) could contribute.
This study tested the hypothesis that there is an interactive effect of DPP4 inhibition and ACE inhibition (vs antihypertensive control subjects) on vasoactive peptides after a mixed meal.
Fifty-three patients with type 2 diabetes and hypertension were randomized to double-blind treatment with ramipril, valsartan, or amlodipine for 15 weeks in parallel groups. During the 5th, 10th, and 15th weeks, participants also received placebo + placebo, sitagliptin 100 mg/d + placebo, and sitagliptin + aprepitant 80 mg/d in random order. On the last day of each crossover treatment, participants underwent a mixed-meal study.
Sitagliptin increased postprandial glucagon-like peptide-1 and decreased glucose in all antihypertensive groups. Sitagliptin increased NPY 1-36 and decreased Y2 agonists NPY 3-36 and PYY 3-36 in all groups. During ramipril or valsartan, but not amlodipine, sitagliptin increased postprandial norepinephrine; substance P receptor blockade with aprepitant prevented this effect. Despite increased norepinephrine, sitagliptin decreased postprandial blood pressure during ACE inhibition.
DPP4 inhibition increases postprandial concentrations of the Y1 agonist NPY 1-36. During treatment with an ACE inhibitor or angiotensin receptor blocker, DPP4 inhibition increased postprandial norepinephrine through a substance P receptor-dependent mechanism. Increased NPY 1-36 and norepinephrine could increase risk of heart failure but did not result in higher postprandial blood pressure.
Mots-clé
DPP4, dipeptidyl peptidase-4 inhibition, hypertension, sitagliptin, substance P, type 2 diabetes mellitus
Pubmed
Open Access
Oui
Création de la notice
20/09/2019 22:33
Dernière modification de la notice
30/04/2021 7:12
Données d'usage